DATA GRAPHICS | Data Byte
BMS awaits decisions on two new indications for Breyanzi; therapies from Ascendis, Dynavax also up for approvals
By Gunjan Ohri, Data Content Analyst
May 2, 2024 12:29 AM UTC
FDA has set target action dates in May for at least four applications, two of which are seeking new indications for BMS’s CAR T therapy Breyanzi.
Since its first approval in 2021 for third-line large B cell lymphoma, CD19 CAR T therapy Breyanzi lisocabtagene maraleucel from Bristol Myers Squibb Co. (NYSE:BMY) has advanced into second-line LBCL, and in March, was granted accelerated approval to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) following use of Btk and BCL2 inhibitors…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652290/four-pdufa-dates-coming-in-may